Abstract
Stereotyped B-cell receptors (BCR) are frequent in patients with chronic lymphocytic leukemia (CLL). In cell culture and in mouse models of CLL, immunogenic epitopes of these BCRs were shown to trigger specific T-cell responses and to control leukemia development. These results suggest vaccination with autologous BCR-derived peptides as a novel therapy for CLL.
See related article by Rovida et al., p. xxx
Footnotes
Clin Cancer Res 2021;XX:XX–XX
- Received October 28, 2020.
- Revision received November 15, 2020.
- Accepted November 24, 2020.
- Published first December 2, 2020.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
This OnlineFirst version was published on January 12, 2021
doi: 10.1158/1078-0432.CCR-20-3977
Antibody Peptides as Cancer Vaccine—Turning Weapons to Targets
Jump to section
Advertisement